OBJECTIVES: To study a possible association between mannan-binding lectin genotypes and severe infections in patients with multiple myeloma receiving moderate strength induction chemotherapy. METHODS: Chemotherapy-related infections were identified retrospectively using clinical records and database files. Mannan-binding lectin genotypes were identified with polymerase chain reaction on stored samples of stem cells or formalin-fixed paraffin-embedded bone marrow biopsies. RESULTS: We included 138 myeloma patients. In five patients, data were incomplete, and 133 patients were analysed. Eighty-eight patients were homozygous for wild-type MBL2 (AA) and forty-five patients were heterozygous or homozygous for variant genotypes (AO/OO). A total of 390 chemotherapy cycles were reviewed. Common Toxicity Criteria grades 3 and 4 infections in general were seen in relation to 104 cycles and were not more common in patient with variant MBL2 (P = 0.90). Septicaemia was seen after 10% of chemotherapy cycles in AA patients vs. 15% in AO/OO patients (P = 0.15). In multi-variate analyses, we found indication of a reduced risk of septicaemia in AA patients [OR 0.27 (0.08-0.90), P = 0.03], after first chemotherapy cycle, but reduction of the risk including all cycles was not significant. A similar trend was seen for grades 3 and 4 infections in general. CONCLUSIONS: During induction chemotherapy in patients with multiple myeloma, a general protective effect of wild-type MBL2 against chemotherapy-related infections was not apparent in this study. However, we found indications of a reduced occurrence of septicaemia in patients with wild-type compared with variant MBL2. Further studies in larger cohorts of patients are relevant.
OBJECTIVES: To study a possible association between mannan-binding lectin genotypes and severe infections in patients with multiple myeloma receiving moderate strength induction chemotherapy. METHODS: Chemotherapy-related infections were identified retrospectively using clinical records and database files. Mannan-binding lectin genotypes were identified with polymerase chain reaction on stored samples of stem cells or formalin-fixed paraffin-embedded bone marrow biopsies. RESULTS: We included 138 myelomapatients. In five patients, data were incomplete, and 133 patients were analysed. Eighty-eight patients were homozygous for wild-type MBL2 (AA) and forty-five patients were heterozygous or homozygous for variant genotypes (AO/OO). A total of 390 chemotherapy cycles were reviewed. Common Toxicity Criteria grades 3 and 4 infections in general were seen in relation to 104 cycles and were not more common in patient with variant MBL2 (P = 0.90). Septicaemia was seen after 10% of chemotherapy cycles in AA patients vs. 15% in AO/OO patients (P = 0.15). In multi-variate analyses, we found indication of a reduced risk of septicaemia in AA patients [OR 0.27 (0.08-0.90), P = 0.03], after first chemotherapy cycle, but reduction of the risk including all cycles was not significant. A similar trend was seen for grades 3 and 4 infections in general. CONCLUSIONS: During induction chemotherapy in patients with multiple myeloma, a general protective effect of wild-type MBL2 against chemotherapy-related infections was not apparent in this study. However, we found indications of a reduced occurrence of septicaemia in patients with wild-type compared with variant MBL2. Further studies in larger cohorts of patients are relevant.
Authors: E Eleutherakis-Papaiakovou; M-A Dimopoulos; E Kastritis; D Christoulas; M Roussou; M Migkou; M Gavriatopoulou; D Fotiou; I Panagiotidis; D C Ziogas; N Kanellias; C Papadimitriou; E Terpos Journal: Bone Marrow Transplant Date: 2017-08-14 Impact factor: 5.483
Authors: Jessica M van der Bol; Floris A de Jong; Ron H van Schaik; Alex Sparreboom; Marianne A van Fessem; Fleur E van de Geijn; Paul L van Daele; Jaap Verweij; Stefan Sleijfer; Ron H Mathijssen Journal: Oncologist Date: 2010-10-07
Authors: Karin Olson; A Robert Turner; Kerry S Courneya; Catherine Field; Godfrey Man; Marilyn Cree; John Hanson Journal: Support Care Cancer Date: 2007-07-24 Impact factor: 3.603
Authors: Jyotshna Mandal; Bijaya Malla; Rudi Steffensen; Luigi Costa; Adrian Egli; Marten Trendelenburg; Francesco Blasi; Kostantinos Kostikas; Tobias Welte; Antoni Torres; Renaud Louis; Wim Boersma; Branislava Milenkovic; Joachim Aerts; Gernot G U Rohde; Alicia Lacoma; Katharina Rentsch; Michael Roth; Michael Tamm; Daiana Stolz Journal: Respir Res Date: 2015-12-18
Authors: Anna S Świerzko; Mateusz Michalski; Anna Sokołowska; Mateusz Nowicki; Łukasz Eppa; Agnieszka Szala-Poździej; Iwona Mitrus; Anna Szmigielska-Kapłon; Małgorzata Sobczyk-Kruszelnicka; Katarzyna Michalak; Aleksandra Gołos; Agnieszka Wierzbowska; Sebastian Giebel; Krzysztof Jamroziak; Marek L Kowalski; Olga Brzezińska; Steffen Thiel; Jens C Jensenius; Katarzyna Kasperkiewicz; Maciej Cedzyński Journal: Front Immunol Date: 2018-09-20 Impact factor: 7.561